General Information of This Antibody
Antibody ID
ANTI0XBPWS
Antibody Name
FL1
Organization
The Finsen Laboratory.; Biotech Research & Innovation Centre (BRIC), Faculty of Health and Medical Sciences, University of Copenhagen.
Synonyms
FL1
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Murine lgG1
Antigen Name
Urokinase-type plasminogen activator (Plau)
 Antigen Info 
Click to Show/Hide the Sequence Information of This Antibody
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
FL1-PNU [Investigative]
Revealed Based on the Cell Line Data
Click To Hide/Show 8 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.005 nM
High uPAR expression (uPAR +++)
Method Description
Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.

   Click to Show/Hide
In Vitro Model Breast adenocarcinoma MDA-MB-231 cells CVCL_0062
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.02 nM
High uPAR expression (uPAR +++)
Method Description
Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.

   Click to Show/Hide
In Vitro Model Pancreatic ductal adenocarcinoma KPC2 cells Mus musculus
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.03 nM
High uPAR expression (uPAR +++)
Method Description
Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.

   Click to Show/Hide
In Vitro Model Pancreatic ductal adenocarcinoma KPC1 cells Mus musculus
Experiment 4 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.05 nM
Moderate uPAR expression (uPAR++)
Method Description
Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.

   Click to Show/Hide
In Vitro Model Pancreatic ductal adenocarcinoma BxPC-3 cells CVCL_0186
Experiment 5 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.08 nM
High uPAR expression (uPAR +++)
Method Description
Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.

   Click to Show/Hide
In Vitro Model Pancreatic ductal adenocarcinoma AsPc1 cells CVCL_0152
Experiment 6 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.3 nM
Moderate uPAR expression (uPAR++)
Method Description
Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.

   Click to Show/Hide
In Vitro Model Pancreatic ductal adenocarcinoma MIA PaCa-2 cells CVCL_0428
Experiment 7 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50)
12 nM
Negative uPAR expression (uPAR-)
Method Description
Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.

   Click to Show/Hide
In Vitro Model Pancreatic ductal adenocarcinoma KPC2 cells (uPAR KO) Mus musculus
Experiment 8 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Effective Concentration (EC50)
17 nM
Negative uPAR expression (uPAR-)
Method Description
Cells, plated in triplicates at 3 × 103 cells per well in 96-well plates, were dosed with eight series of fourfold serially diluted PNU conjugates, unconjugated FL1, and free toxin (Creative Biolabs, #ADC-P-025) in 100 ul of complete growth media. Control cells were incubated with PBS-supplemented media. Cell viability was measured after 3 or 5 days of incubation, using CellTiter 96 Aqueous one-solution cell-proliferation assay reagent (MTS, Promega, #G358), as per the vendor's recommendations. Plate absorbance was then measured at 490 and 650 nm (for background subtraction) using a Spectra Max Plus plate reader (Molecular Devices). Data were plotted as a function of drug concentration (nanomolar) in GraphPad Prism 9 and fitted to a four-parameter nonlinear regression function, from which EC50 values were derived.

   Click to Show/Hide
In Vitro Model Pancreatic ductal adenocarcinoma KPC1 cells (uPAR KO) Mus musculus
References
Ref 1 Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models